Evidence map›Paper›PMID 40533663›Full record

ReviewMedical oncology (Northwood, London, England)2025

Enter sandman: how to tackle dormant breast cancer cells.

Fouad Attieh, Reina Al Khatib, Marc Boutros, Antoine Mouawad, Hampig Raphaël Kourie

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fouad AttiehFaculty of Medicine, Saint Joseph University of Beirut, Beirut, 11072180, Lebanon. fouad.attieh@net.usj.edu.lb.ORCID http://orcid.org/0000-0002-2599-5521
Reina Al KhatibFaculty of Medicine, Saint Joseph University of Beirut, Beirut, 11072180, Lebanon.ORCID http://orcid.org/0009-0006-7553-5247
Marc BoutrosFaculty of Medicine, Saint Joseph University of Beirut, Beirut, 11072180, Lebanon.ORCID http://orcid.org/0000-0003-1765-4222
Antoine MouawadFaculty of Medicine, Saint Joseph University of Beirut, Beirut, 11072180, Lebanon.ORCID http://orcid.org/0000-0002-0259-0898
Hampig Raphaël KourieDepartment of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 11072180, Lebanon.ORCID http://orcid.org/0000-0002-2502-5402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer dormancy poses a major challenge in oncology, often leading to relapse and metastasis years after initial treatment. This phenomenon is driven by the ability of dormant cancer cells to evade immune detection and resist chemotherapy. Thus, these cells remain in a quiescent state until conditions favor their reactivation. A deeper understanding of the mechanisms governing dormancy-including cellular signaling pathways, the role of the tumor microenvironment, and immune system interactions-is essential for developing effective and practical therapeutic interventions. Recent research has highlighted three primary strategies for targeting dormant breast cancer cells: the killing strategy, the sleeping strategy, and the awakening strategy. This review explores the various techniques used to detect dormant breast cancer cells and evaluates experimental therapeutic approaches aimed at either eradicating or controlling them. By synthesizing the latest advancements in cancer dormancy research, this article provides valuable insights for oncologists while remaining accessible to a broader audience.

Indexed as

Breast NeoplasmsFemaleHumansSignal TransductionTumor MicroenvironmentAwakening strategyCancer dormancyDormant breast cancerKilling strategyLiquid biopsySleeping strategy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.